<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01949688</url>
  </required_header>
  <id_info>
    <org_study_id>SUMS-22-15</org_study_id>
    <secondary_id>22-15</secondary_id>
    <nct_id>NCT01949688</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 or A*02-positive Advanced Solid Tumors</brief_title>
  <official_title>Phase I/II Study Using Epitope Peptide Restricted to HLA-A*24 or HLA-A*02 in Patients With Advanced Solid Tumors That Are Refractory to Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiga University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tokyo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shiga University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators examine using a combination of two types of HLA-A*2402 (or
      HLA-A*0201)-restricted epitope peptides, which were derived from VEGF-R1 and VEGF-R2 the
      safety, immunogenicity, and antitumor effect of vaccine treatment for advanced solid tumor
      patients who are refractory to standard therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, immune response and
      clinical efficacies of HLA-A*2402 or HLA-A*0201 restricted epitope peptides (VEGF-R1 and
      VEGF-R2) emulsified with Montanide ISA 51 for advanced solid tumors.

      In this phase I/II trial, the investigators examine using a combination of the two peptides
      the safety, immunogenicity, and antitumor effect of vaccine treatment for HLA-A*2402 or
      HLA-A*0201-positive advanced solid tumor patients who are refractory to standard therapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of safety: the number of adverse events of vaccination therapy.</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of clinical efficacy: Overall survival.</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Various immunological responses including peptides specific CTL, antigen cascade, regulatory T cells, cancer antigens and HLA levels.</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of clinical efficacy: Progression free survival.</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of clinical efficacy: Tumor markers.</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of clinical efficacy: Objective response rate.</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>HLA-A*2402 restricted peptides</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLA-A*2402 restricted peptides with adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HLA-A*0201 restricted peptides</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLA-A*0201 restricted peptides with adjuvant</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HLA-A*2402 or A*0201 restricted peptides</intervention_name>
    <description>Open Label, Non-Randomized, Safety/Efficacy study:
HLA-A*2402-positive patients will be vaccinated subcutaneously once a week with HLA-A*2402 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant.
HLA-A*0201-positive patients will be vaccinated subcutaneously once a week with HLA-A*0201 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant.</description>
    <arm_group_label>HLA-A*2402 restricted peptides</arm_group_label>
    <arm_group_label>HLA-A*0201 restricted peptides</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Advanced solid tumors that are refractory to standard therapies or that cannot be
             treated with those due to medical reason.

          2. ECOG performance status 0-1

          3. Age between 20 to 85

          4. Clinical efficacy can be evaluated by some methods

          5. No prior chemotherapy, radiation therapy, hyperthermia or immunotherapy within two
             weeks

          6. Life expectancy &gt; 3 months

          7. Laboratory values as follows 1500/mm3 &lt; WBC &lt; 10000/mm3 Platelet count &gt; 75000/mm3 15%
             &lt; Lymphcyte fraction Asparate transaminase &lt; 3 X cutoff value Alanine transaminase &lt; 3
             X cutoff value Total bilirubin &lt; 3 X cutoff value Serum creatinine &lt; 2X cutoff value

          8. HLA-A*2402 or HLA-A*0201

          9. Able and willing to give valid written informed consent

        Exclusion Criteria:

          1. Active and uncontrolled cardiac disease (i.e. coronary syndromes, arrhythmia)

          2. Myocardial infarction within six months before entry

          3. Breastfeeding and Pregnancy (woman of child bearing potential)

          4. Active and uncontrolled infectious disease

          5. Concurrent treatment with steroids or immunosuppressing agent

          6. Other malignancy requiring treatment

          7. Non-cured traumatic wound

          8. Decision of unsuitableness by principal investigator or physician-in-charge
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yataro Daigo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shiga University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yataro Daigo, MD, PhD</last_name>
    <phone>1-81-77-548-2111</phone>
    <email>ydaigo@belle.shiga-med.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shiga University of Medical Science Hospital</name>
      <address>
        <city>Ohtsu</city>
        <state>Shiga</state>
        <zip>520-2192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2013</study_first_submitted>
  <study_first_submitted_qc>September 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2013</study_first_posted>
  <last_update_submitted>September 20, 2013</last_update_submitted>
  <last_update_submitted_qc>September 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiga University</investigator_affiliation>
    <investigator_full_name>Yataro Daigo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

